Literature DB >> 23380456

Enhancement of T cell-mediated immune responses to whole inactivated influenza virus by chloroquine treatment in vivo.

Bruno Garulli1, Giuseppina Di Mario, Ester Sciaraffia, Daniele Accapezzato, Vincenzo Barnaba, Maria R Castrucci.   

Abstract

Current influenza vaccines induce poor cross-reactive CD8+ T cell responses. Cellular immunity is generally specific for epitopes that are remarkably conserved among different subtypes, suggesting that strategies to improve the cross-presentation of viral antigens by dendritic cells (DC) could elicit a broadly protective immune response. Previous studies have shown that limited proteolysis within the endocytic pathway can favorably influence antigen processing and thus immune responses. Herein, we demonstrate that chloroquine improves the cross-presentation of non-replicating influenza virus in vitro and T cell responses in mice following a single administration of inactivated HI-X31 virus. CD8+ T cells were also recruited to lymph nodes draining the site of infection and able to reduce viral load following pulmonary challenge with the heterologous PR8 virus. These findings may have implications for vaccination strategies aimed at improving the cross-presentation capacity of DCs and thus the size of effector and memory CD8+ T cells against influenza vaccines.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23380456     DOI: 10.1016/j.vaccine.2013.01.037

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine.

Authors:  Geert Leroux-Roels; Patricia Bourguignon; Julie Willekens; Michel Janssens; Frédéric Clement; Arnaud M Didierlaurent; Laurence Fissette; François Roman; Dominique Boutriau
Journal:  Clin Vaccine Immunol       Date:  2014-01-03

2.  Studying the effect of chloroquine on sporozoite-induced protection and immune responses in Plasmodium berghei malaria.

Authors:  Else M Bijker; Krystelle Nganou-Makamdop; Geert-Jan van Gemert; Fidel Zavala; Ian Cockburn; Robert W Sauerwein
Journal:  Malar J       Date:  2015-03-26       Impact factor: 2.979

3.  Sporozoite immunization of human volunteers under mefloquine prophylaxis is safe, immunogenic and protective: a double-blind randomized controlled clinical trial.

Authors:  Else M Bijker; Remko Schats; Joshua M Obiero; Marije C Behet; Geert-Jan van Gemert; Marga van de Vegte-Bolmer; Wouter Graumans; Lisette van Lieshout; Guido J H Bastiaens; Karina Teelen; Cornelus C Hermsen; Anja Scholzen; Leo G Visser; Robert W Sauerwein
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

Review 4.  Progress in Treatment of Viral Infections in Children with Acute Lymphoblastic Leukemia.

Authors:  Maria Moschovi; Maria Adamaki; Spiros A Vlahopoulos
Journal:  Oncol Rev       Date:  2016-06-30

Review 5.  Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virus.

Authors:  R Gasparini; D Amicizia; P L Lai; N L Bragazzi; D Panatto
Journal:  J Prev Med Hyg       Date:  2014-12

Review 6.  Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases.

Authors:  Md Abdul Alim Al-Bari
Journal:  Pharmacol Res Perspect       Date:  2017-01-23

Review 7.  Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?

Authors:  Sebastián Ibáñez; Oriela Martínez; Francisca Valenzuela; Francisco Silva; Omar Valenzuela
Journal:  Clin Rheumatol       Date:  2020-06-03       Impact factor: 2.980

8.  pH-Responsive Micelle-Based Cytoplasmic Delivery System for Induction of Cellular Immunity.

Authors:  Eiji Yuba; Naoki Sakaguchi; Yuhei Kanda; Maiko Miyazaki; Kazunori Koiwai
Journal:  Vaccines (Basel)       Date:  2017-11-04

9.  New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?

Authors:  Christian A Devaux; Jean-Marc Rolain; Philippe Colson; Didier Raoult
Journal:  Int J Antimicrob Agents       Date:  2020-03-12       Impact factor: 5.283

Review 10.  Drug repurposing against COVID-19: focus on anticancer agents.

Authors:  Gennaro Ciliberto; Rita Mancini; Marco G Paggi
Journal:  J Exp Clin Cancer Res       Date:  2020-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.